RNA elements within flavivirus genomes are potential targets for antiviral therapy. A panel of phosphorodiamidate morpholino oligomers (PMOs), whose sequences are complementary to RNA elements located in the 5-and 3-termini of the West Nile (WN) virus genome, were designed to anneal to important cis-acting elements and potentially to inhibit WN infection. A novel Arg-rich peptide was conjugated to each PMO for efficient cellular delivery. These PMOs exhibited various degrees of antiviral activity upon incubation with a WN virus luciferase-replicon-containing cell line. Among them, PMOs targeting the 5-terminal 20 nucleotides (5End) or targeting the 3-terminal element involved in a potential genome cyclizing interaction (3CSI) exhibited the greatest potency. When cells infected with an epidemic strain of WN virus were treated with the 5End or 3CSI PMO, virus titers were reduced by approximately 5 to 6 logs at a 5 M concentration without apparent cytotoxicity. The 3CSI PMO also inhibited mosquito-borne flaviviruses other than WN virus, and the antiviral potency correlated with the conservation of the targeted 3CSI sequences of specific viruses. Modeof-action analyses showed that the 5End and 3CSI PMOs suppressed viral infection through two distinct mechanisms. The 5End PMO inhibited viral translation, whereas the 3CSI PMO did not significantly affect viral translation but suppressed RNA replication. The results suggest that antisense PMO-mediated blocking of cis-acting elements of flavivirus genomes can potentially be developed into an anti-flavivirus therapy. In addition, we report that although a full-length WN virus containing a luciferase reporter (engineered at the 3 untranslated region of the genome) is not stable, an early passage of this reporting virus can be used to screen for inhibitors against any step of the virus life cycle.
Many members of the Flavivirus genus, a group of arthropod-borne viruses in the family Flaviridae, cause significant human diseases; among these, West Nile (WN), dengue (DEN), Japanese encephalitis (JE), yellow fever (YF), Murray Valley encephalitis, and tick-borne encephalitis (TBE) viruses are emerging and reemerging pathogens (7) . Approximately 50 to 100 million human cases of DEN virus infection occur annually (29) . The recent epidemics of WN virus have caused significant morbidity and mortality in the United States (9) . Vaccines for humans are available only for YF, JE, and TBE viruses (7) . No drug therapy is currently available to treat flavivirus infections. It is therefore of great importance to public health to develop an efficacious drug therapy against flaviviruses.
Flavivirus virions are spherical in shape, with a diameter of approximately 50 nm (21) . The flavivirus genome is a singlestranded, plus-sense RNA of approximately 11 kb in length. The genomic RNA consists of a 5Ј untranslated region (UTR), a single long open reading frame (ORF), and a 3Ј UTR (43) . The single ORF encodes a polyprotein that is co-and posttranslationally processed by viral and cellular proteases into three structural proteins (capsid [C] , premembrane or membrane, and envelope) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (10) . Nonstructural proteins are primarily involved in viral RNA replication as components of a replicase complex, but they may also function in viral assembly (22, 24) and antiimmune responses (38) . Upon flavivirus infection, the genomic plus-strand RNA is translated to produce viral proteins and transcribed into a complementary minus-strand RNA, which in turn serves as the template for the synthesis of more plus-strand genomic RNA (10) .
The 5Ј and 3Ј UTRs of the flavivirus genome are approximately 100 and 400 to 700 nucleotides (nt) in length, respectively. Besides several conserved sequence (CS) elements, both the 5Ј-and 3Ј-terminal sequences of the genomic RNA can form highly conserved stem-loop structures (5, 6, 27, 41, 43, 45, 54) . Previous studies showed that the conserved RNA sequence and structures are critical for flavivirus replication (3, 8, 12, 19, 20, 25, 28, 31, 52, 53, 56, 57) . Host and viral proteins (including NS3 and NS5) were found to interact with the 3Ј UTR of the flavivirus genome (2, 11, 14, 23, 50, 51) . These results suggest that the 5Ј and 3Ј UTRs direct the processes of flavivirus translation and RNA replication through interactions with viral RNA elements, viral proteins, and the host protein(s) in a regulated manner. However, the molecular details of how these conserved sequence and structural elements modulate viral translation and RNA replication remain unknown.
Using WN virus, we recently showed that specific sequence and structural elements within the 3Ј-terminal region of the genomic RNA are required for viral replication. (i) Potential genome cyclization mediated by base-pairing interaction (Fig. 1A) FIG. 1. Sequence selection and cellular delivery of PMOs. (A) WN virus genome. Terminal stem-loop structures and a potential genome cyclization are enlarged to display regions where antisense PMOs target to. Individual PMOs are indicated by their names and targeted regions (bracketed lines). WN virus genome cyclization is mediated through a perfect 12-nt base-pairing interaction (dotted lines) between the 5ЈCS and 3ЈCSI sequences (boxed sequence). A pseudoknot (Pskt) interaction within the 3Ј stem-loop (45) is indicated by dashed lines. The major binding sites of host protein EF1␣ (2) is depicted by ovals. The flavivirus-conserved pentanucleotide located at the top of the 3Ј stem-loop (55) is underlined. The AUG initiation codon of the ORF is in boldface type. (B) PMO sequences. All PMOs contain an Arg-rich peptide at their 5Ј ends, designated P007. An extra C (italicized) was added to the 3Ј end of the 5ЈEnd PMO to potentially interact with the 7-methylguanylate of the 5Ј cap and to further stabilize its hybridization with the viral genome. (C) Structure of P007-PMOs. In a PMO, the ribose of RNA is replaced by a morpholine ring, and the phosphodiester internucleotide bond is replaced by a phosphorodiamidate linkage. The CH 3 CONH-(RAhxR) 4 -Ahx-␤Ala sequence was attached to each PMO through a piperazine linker, where R stands for arginine, Ahx stands for 6-aminohexanoic acid, and ␤Ala stands for beta-alanine. (D) Enhancement of cellular delivery of PMOs by P007 conjugation. BHK cells were incubated with the fluorescein-labeled scramble PMO with or without a 5Ј P007 conjugation at a concentration of 10 M. After 15 min of incubation, cells incubated with the P007-conjugated PMO are fluorescence positive (left), whereas no fluorescence is observed in cells incubated with unconjugated PMOs (right).
between the 5ЈCS (within the C coding sequence) and the 3ЈCSI is essential for WN viral RNA synthesis (25) . (ii) The flavivirus-conserved pentanucleotide in the 3Ј stem-loop of the genome (Fig. 1A) requires a specific sequence and structure for RNA synthesis (52) . (iii) The 3Ј-terminal 5-nt region of the genome also requires specific sequence and structure for WN virus replication (53) . These findings, together with earlier results from other flaviviruses, suggest that RNA elements within the terminal regions of the flavivirus genome are critical for viral reproduction and therefore can potentially be targeted for antiviral therapy. In the present study, we explore this possibility by testing the antiviral activities of several phosphorodiamidate morpholino oligomers (PMOs) whose sequences are complementary to various regions of the 5Ј and 3Ј termini of the WN virus genome (Fig. 1A to C) . PMOs are uncharged, water-soluble, nuclease-resistant antisense agents that are typically synthesized to a length of about 20 subunits and contain purine and pyrimidine bases attached to a backbone composed of morpholine rings joined by phosphorodiamidate intersubunit linkages (Fig. 1C) (49) . We show that conjugation of an Arg-rich peptide (Fig. 1C) to the 5Ј end of the PMOs greatly facilitates the delivery of the molecules into cultured cells. PMOs targeting various regions of the 5Ј and 3Ј termini of the viral genome inhibited WN virus infection to various degrees. Among them, a PMO targeting the 5Ј-terminal 20 nt (5ЈEnd) and a PMO targeting the 3ЈCSI showed the greatest antiviral activities. The 5ЈEnd and 3ЈCSI PMOs inhibit the WN virus life cycle primarily through suppression of viral translation and RNA replication, respectively.
MATERIALS AND METHODS

Cells and viruses.
Three types of cells were used in this study. (i) BHK-21 (baby hamster kidney) cells were grown in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). (ii) A reporting BHK cell line containing persistently replicating WN virus replicon with dual reporter genes, Renilla luciferase (Rluc) and neomycin phosphotransferase (RlucNeoRep) ( Fig.  2A) , was maintained in DMEM with 10% FBS and 1 mg of G418/ml (26) . (iii) Vero cells (African green monkey kidney cells; ATCC CCL-81) were cultured in minimal essential medium supplemented with 2% FBS, 2 mM L-glutamine, 0.3% sodium bicarbonate, 100 U of penicillin/ml, and 100 g of streptomycin/ml. All cells were maintained in 5% CO 2 at 37°C. WN virus strain 3356, an isolate from the kidney of an American crow collected in 2000 from New York (15), was used for antiviral assays. Viral RNA derived from the same isolate was used to prepare all constructs used in this study, including various reporting replicons (46) and the full-length luciferase virus.
Construction of a full-length WN virus that contains a luciferase reporter. An infectious cDNA clone of the epidemic WN virus isolate 3356 (47) was used to construct a luciferase-reporting full-length virus. An Rluc reporter driven by an encephalomyocarditis virus internal ribosomal entry site (EMCV IRES) was inserted into the WN virus 3Ј UTR at nucleotide position 10,436 (GenBank accession number AF404756), resulting in RlucWN virus (Fig. 3A) . The RlucWN cDNA plasmid was prepared by swapping the SpeI-SacII fragment (nt 8,022 to 10,822) between the wild-type infectious clone (47) and a replicon clone containing the IRES-Rluc insertion (25) . The RlucWN RNA was in vitro transcribed and transfected into BHK cells as previously described (25) . The resulting RlucWN virus was harvested at day 3 posttransfection (p.t.) when the cytopathic effect (CPE) of the transfected cells was apparent.
PMOs. Nine PMOs of 20 to 23 bases in length were synthesized. The sequences of the PMOs and their potential base pairing regions are detailed in Fig.  1A and B. A scramble PMO containing a random sequence was synthesized as a nonviral negative control (Fig. 1B) . For efficient delivery of PMOs into cells, an Arg-rich peptide [CH 3 CONH-(RAhxR) 4 -Ahx-␤Ala, designated P007; R stands for arginine, Ahx stands for 6-aminohexanoic acid, and ␤Ala stands for betaalanine] was covalently conjugated to the 5Ј end of the PMOs through a noncleavable piperazine linker (Fig. 1C) . The effect of the Arg-rich peptide on cellular delivery of PMOs was examined by incubating BHK cells with a 3Ј-fluoresceinated scramble PMO with or without the 5Ј P007 conjugation (Fig.  1D) . The methods for synthesis of PMOs, conjugation of P007, and purification and analysis of P007-PMOs were similar to those previously described (37, 49) . The PMOs were dissolved in sterile water at 2 mM, aliquoted, stored in the dark at Ϫ20°C, and used in antiviral assays without multiple rounds of freeze and thaw. All assays were performed by direct addition of the PMOs to cell culture medium (described above) without changing the FBS concentration. Antiviral assays. Three types of antiviral assays were performed in this study. (i) A WN virus reporting cell line containing persistently replicating replicons with dual reporter genes (RlucNeoRep) ( Fig. 2A ) was used to screen PMOs for antiviral activities. Construction and characterization of the WN virus reporting cell line were described previously (26) . For assay of the antiviral activities of PMOs, approximately 2 ϫ 10 5 cells (in a total volume of 0.8 ml) were seeded in each well of 12-well plates in DMEM with 10% FBS without G418. PMOs were added to the medium at 16 h postseeding. After 24 h of PMO treatment, cells were lysed and assayed for Rluc activities with an Rluc assay kit (Promega, Madison, Wis.).
(ii) A full-length WN virus containing a luciferase reporter (RlucWN) ( Mo.), and 3-deazauridine was purchased from MP Biomedicals, Inc. (Ëschwege, Germany). All compounds were dissolved in dimethyl sulfoxide (DMSO) and added to cells in medium with a final DMSO concentration of 1%. Cells not treated with compounds were also treated with 1% DMSO as a negative control. Briefly, compounds were added to Vero cells at 80% confluency in 12-well plates with 1.5 ml of minimal essential medium plus 2% FBS per well. Immediately after compound addition, cells were infected with RlucWN virus at a multiplicity of infection (MOI) of 0.5. Rluc activities were assayed at 24 h postincubation (p.i.). Based on the Rluc signal and compound concentration curves (Fig. 3C ), regression analysis (SAS, version 6.12; SAS Institute, Inc., Cary, N.C.) was performed to calculate the compound concentration required for 50% inhibition of Rluc activity (EC 50 ) for each inhibitor. Once the RlucWN-virus-based assay had been validated with known WN virus inhibitors as described above, a similar procedure was used to evaluate the antiviral activities of selected PMOs (Fig. 4A ).
(iii) WN virus isolate 3356 was used to verify the effectiveness of the two most potent PMOs (5ЈEnd and 3ЈCSI) and a moderately active PMO (AUG-I) in a viral yield reduction assay (Fig. 5) . A protocol similar to that used for the RlucWN virus infection assay was performed (described above) except that (i) Vero cells were infected at an MOI of 0.1, and (ii) virus titer reductions were measured at 42 h postinfection, when CPE was clearly observed in untreated cells. The titer of the virus yield in supernatant was determined by plaque assays on Vero cells (47) . A similar protocol was used for analyzing the antiviral MTT cytotoxicity assay. Vero cells grown to confluence in 96-well plates were incubated with selected PMOs in medium identical to that used for the viral infection assay. After incubation with PMOs for 24 h, cell proliferation (viability) was assessed with a tetrazolium colorimetric assay kit (American Type Culture Collection, Manassas, Va.). Briefly, 10 l of MTT reagent [3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] was added to each well. Cells were incubated for 2.5 h at 37°C until the purple precipitate was clearly visible by light microscopy. Detergent reagent was then added, and cells were further incubated overnight at room temperature in the dark to ensure that all formazan crystals were dissolved. The plates were read at 570 nm with an automatic plate reader.
Cell viability was presented as the percentage of absorbance at 570 nm derived from the PMO-treated cells relative to absorbance derived from the untreated cells.
Mode-of-action analysis. A reporting replicon containing an Rluc gene (fused in frame with the ORF in the position where the viral structural region was deleted) was used to differentiate PMO-mediated inhibition of viral translation from inhibition of RNA replication (RlucRep) (Fig. 6A ). We previously demonstrated that Rluc signals derived from the RlucRep-transfected cells at 2 to 10 h and after 24 h p.t. represent initial translation of input RNA and translation of replicating viral RNA, respectively (25) . To adapt the system to a mode-ofaction study, we electroporated 8 ϫ 10 6 BHK cells with 10 g of RNA, as reported previously (25) . The transfected cells were suspended in 25 ml of DMEM with 10% FBS. Three milliliters of cell suspension was added to six-well plates containing preseeded PMOs to a final concentration of 7.5 M and was assayed for Rluc activity at 2 h p. 
RESULTS
Sequence selection of PMOs for targeting terminal regions of the WN virus genome. Nine antisense PMOs were synthesized to target various RNA elements within the terminal regions of the WN virus genome ( Fig. 1A and B) . The 5ЈEnd PMO was designed to contain a sequence capable of basepairing with the first 20 nt of the genome. An extra C (Fig. 1B) was added to the 3Ј end of the 5ЈEnd PMO to potentially interact with the 7-methylguanylate of the 5Ј cap and to further stabilize its hybridization with the viral genome. Two PMOs, AUG-I and AUG-II, were prepared to block viral translation through base pairing with a region spanning the initiation . 1A ) of the viral ORF. The 5ЈCS and 3ЈCSI PMOs were synthesized to interfere with a potential genome cyclization (17) mediated through a perfect 12-nt base-pair interaction (Fig. 1A) . The pseudoknot (Pskt) PMO was designed to invade a region that had been previously reported to form a pseudoknot structure (Fig. 1A ) (45) . The 3ЈStem PMO was synthesized to base pair with a region containing the major binding site of the host protein EF1␣ (5Ј-CACA-3Ј) (Fig. 1A) (2). The 3ЈLoop PMO was prepared to target a flavivirusconserved pentanucleotide (Fig. 1A ) located at the top loop of the 3Ј stem-loop (55) . The 3ЈEnd PMO was designed to base pair with the 3Ј-terminal 20 nt of the genome. In addition, a scramble PMO was synthesized to contain a random sequence as a nonviral negative control. Enhancement of cellular delivery of PMOs by an Arg-rich peptide. PMOs conjugated with a short positively charged peptide resembling a putative translocation domain of the human immunodeficiency virus type 1 Tat protein were shown to penetrate cultured cells much more efficiently than PMOs lacking such a peptide conjugation (36, 37) . A new type of Arg-rich peptide conjugate, designated P007 (Fig. 1C) , was synthesized and examined for its effect on cellular delivery of PMOs. BHK cells were incubated with a fluorescein-labeled scramble PMO conjugated with or without a P007 peptide. Remarkably, fluorescent microscopic analyses showed that all cells incubated with the P007-conjugated PMO (at 10 M) were fluorescence positive at 15 min p.i. (Fig. 1D, left) . The fluorescent intensity increased during the first 2 h of incubation and reached saturation afterwards (data not shown). Although the fluorescence was distributed throughout the cells, signals were concentrated at the nucleus. In contrast, no fluorescence was observed in cells incubated with the PMO lacking a P007-conjugation (Fig.  1D, right) . Longer incubation of cells with non-P007-conjugated PMO (up to 4 h) did not elicit any fluorescent signal (data not shown). The results clearly demonstrated that P007 enhanced delivery of PMOs into cultured cells. Therefore, all PMOs used in the following experiments were synthesized to contain a P007 conjugation.
PMOs targeting various RNA elements within the termini of WN virus genome inhibit viral replication to various degrees. We initially screened the antiviral activities of the PMOs in a WN virus replicon-reporting cell line (26) . The reporting cell line harbors a persistently replicating replicon that contains dual reporter genes, Renilla luciferase (Rluc) and neomycin phosphotransferase (RlucNeoRep) (Fig. 2A) . We previously showed that Rluc activity derived from the replication of RlucNeoRep within the cell line could be used to estimate the antiviral activities of WN virus inhibitors (26) . To examine the effects of PMOs on WN virus replication, we incubated the PMOs with RlucNeoRep-containing cells and assayed for Rluc activity at 24 h after PMO addition. The PMO-mediated inhibition of viral replication was reflected by an inverse dose response between the PMO concentration and the Rluc signal intensity. All four PMOs targeting 5Ј-terminal regions of the genome exhibited antiviral activities with potency decreasing in the order of 5ЈEnd, AUG-I, AUG-II, and 5ЈCS PMOs (Fig.  2B) . Among the five PMOs targeting the 3Ј-terminal regions of the genome, 3ЈCSI showed greatest potency. Three other PMOs (Pskt, 3ЈStem, and 3ЈLoop) exhibited moderate inhibition, whereas 3ЈEnd PMO (targeting the 3Ј-terminal 20 nt of the genome) did not consistently show inhibition (Fig. 2C) . As a control, the scramble PMO with nonviral sequence did not exhibit any inhibition of Rluc activity (Fig. 2B and C) . No significant cytotoxicity was observed at 10 M, the highest concentration tested in the above experiments (see below), indicating that the observed antiviral activities of the PMOs were not due to cytotoxicity. Comparison of the Rluc curves derived from the various PMOs suggests that (i) PMOs targeting different regions of the WN genome inhibit viral replication to differing degrees and (ii) 5ЈEnd and 3ЈCSI are the two most potent inhibitors. Therefore, the following experiments were focused on further analysis of the 5ЈEnd and 3ЈCSI PMOs.
A full-length WN virus containing a luciferase reporter can be used to screen for potential inhibitors of the WN virus life cycle. The RlucNeoRep reporting cell line described above could only be used to screen for inhibitors against viral replication (including viral translation, polyprotein processing, and minus-and plus-strand RNA synthesis), but not viral entry and assembly (due to a deletion of structural C-prM-E genes in the replicon). To facilitate antiviral screening for potential inhibitors against any step of the virus life cycle, we attempted to construct an infectious reporting WN virus by engineering a luciferase gene into the full-length WN virus genome (47) . An Rluc gene driven by an EMCV IRES was inserted at the upstream region of the 3Ј UTR of the genome, resulting in RlucWN virus (Fig. 3A) . Transfection of BHK cells with RlucWN RNA yielded a high-titer reporting virus (up to 10 9 PFU/ml at day 3 p.t.). Infection of cells with the initial virus stock at an MOI of 0.5 resulted in an Rluc signal over 10 5 -fold higher than background level (Fig. 3C) . However, multiple passaging of the reporting virus in BHK cells resulted in sequential decreases in the Rluc signal. By the third round of infection, the Rluc signal was reduced to background level (data not shown). Meanwhile, a high level of infectious virus was maintained during multiple passaging of the virus, as indicated by plaque assays and CPEs from infected cells (data not shown). The results suggest that the RlucWN virus does not stably retain the nonviral reporter.
To determine the exact region(s) of mutation or deletion during the passaging of the reporting virus, we extracted RNAs from wild-type virus (without reporter), first passage of the RlucWN virus (containing a high level of luciferase activity), and seventh passage of the virus (lacking any luciferase activity). Five sets of RT-PCR covering the entire WN virus genome were performed on the extracted RNAs (Fig. 3B) . The results showed that the IRES-Rluc fragment (a total length of 1,520 bp) inserted at nucleotide position 10463 was present at the first passage of the RlucWN virus but was subsequently deleted by the seventh passage of the virus. Sequencing of the reverse transcription-PCR (RT-PCR) product derived from the seventh passage of the reporting virus showed that only the 5Ј-or 3Ј-terminal residues of the IRES-Rluc cassette were retained at the insertion site. Since we did not sequence the entire genome, it is also possible that mutations exist in other regions of the seventh-passage virus.
Although the RlucWN virus is not stable, we argue that the reporting virus could still be useful as a reagent for antiviral screening assays. Incubation of Vero cells (infected with reporting virus stock derived directly from the RlucWN-RNAtransfected cells) with potential inhibitors should reduce the Rluc signal. Comparison of Rluc signals derived from the compound-treated infection with the untreated infection should reveal the potency of the inhibitor. To explore this possibility, we incubated the RlucWN-infected cells (at an MOI of 0.5) with several known WN virus inhibitors (Fig. 3C) . The compounds were added to culture medium at the time of viral infection and were retained in cell culture throughout the assay. As expected, Rluc activities assayed at 24 h p.i. showed an inverse correlation with PMO concentration. Based on the Rluc curves, the EC 50 s were estimated to be 0.34, 0.74, 12, 19, and Ͼ300 M for mycophenolic acid, 6-azauridine, 3-deazauridine, ribavirin, and glycyrrhizin, respectively. The EC 50 s for 6-azauridine (0.74 M), ribavirin (19 M), and glycyrrhizin (Ͼ300 M) agreed well with the EC 50 s derived from an authentic virus infection assay (0.82 M, 3 to 60 M, and 486 M, respectively) (13, 18) . Thus, at early passage, the reporting virus (RlucWN) can potentially be used to screen for inhibitors against WN virus reproduction.
It should be noted that EC 50 values derived from the RlucWN virus assay are lower than those derived from the RlucNeoRep cell line assay ( Fig. 2A) . As described above, the EC 50 s derived from the RlucWN virus assay were estimated to be 0.34, 0.74, and 19 M for mycophenolic acid, 6-azauridine, and ribavirin, respectively (Fig. 3C) , whereas the EC 50 s derived from RlucNeoRep cell line were determined to be 5.4, 11, and 140 M (26). The discrepancy in EC 50 s between the two assay systems is most likely due to the difference in viral replication status when the compound was added. Specifically, in the RlucNeoRep cell-based assay, a high level of replicons has already been replicating inside cells before treatment with a compound, whereas in the RlucWN infection-based assay, compound and virus were added simultaneously to naïve cells.
Once the RlucWN-infection assay had been validated, we employed the assay to evaluate the antiviral activities of the two most potent PMOs (5ЈEnd and 3ЈCSI) and a moderately active PMO (AUG-I). A similar procedure for analyzing known WN inhibitors (Fig. 3C) was performed. As shown in Fig. 4A , Rluc signals were significantly suppressed by the 5ЈEnd, 3ЈCSI, and AUG-II PMOs at 1 M and were further decreased at 5 M. The relative potencies of these PMOs derived from the RlucWN infection assay correlated well with those derived from the replicon-reporting cell line (Fig. 2) . In contrast, the scramble PMO did not exhibit substantial suppression of the Rluc signal. These results again suggest that the RlucWN-reporting virus can be used as an antiviral reagent.
Cytotoxicity of PMOs. An MTT assay was performed to exclude the possibility that the observed inhibition of WN viral infection was due to PMO-mediated cytotoxicity. Vero cells were incubated with various concentrations of 5ЈEnd, 3ЈCSI, AUG-I, or scramble PMO for 24 h. Viability of PMO-treated cells was quantified by cellular metabolism of MTT tetrazolium salt. The results showed that cells incubated in PMO at a concentration up to 10 M maintained a cell viability of around 85%. However, a minor change in cell morphology began to appear when cells were incubated in 10 M PMO (but not at a concentration of Յ7.5 M; data not shown), indicative of a low level of cytotoxicity at 10 M. The cytotoxicity-mediated morphological change of treated cells became more pronounced at a PMO concentration of 20 M (data not shown). The latter observation agreed with the MTT result that cell viability was reduced to about 70% when cells were incubated in 20 M PMO (Fig. 4B) . The results suggest that PMOs cause minor cytotoxicity at 10 M or higher. Therefore, the PMO-mediated inhibition of a WN virus reporting replicon (Fig. 2) or reporting virus (Fig. 4A) was not due to cytotoxicity at concentrations of Ͻ10 M.
Potent inhibition of an epidemic strain of WN virus by PMOs. To validate the authenticity of the observed PMOmediated viral inhibition, we tested the 5ЈEnd, 3ЈCSI, and AUG-I PMOs in a wild-type WN virus infection assay. The PMOs were incubated with Vero cells infected with an epidemic strain of WN virus at an MOI of 0.1. The effects of the PMOs on viral infection were measured by virus titer reduction at 42 h p.t., when the CPE was clearly observed in untreated cells. As shown in Fig. 5 , the 5ЈEnd PMO reduced the virus titer by about 6 logs at 5 M or 10 M. The 3ЈCSI PMO inhibited virus titer by 5 logs at 5 M and 6 logs at 10 M. The AUG-I PMO was less potent, reducing virus titer by nearly 3 logs at 5 M and 5 logs at 10 M. Compared with the 5ЈEnd, 3ЈCSI, and AUG-I PMOs, the scramble PMO did not cause a substantial reduction of virus titer at 1 and 5 M. However, a 2-log reduction of virus titer was observed at a scramble PMO concentration of 10 M. This nonspecific virus titer reduction was most likely due to a low level of cytotoxicity of PMOs at this concentration, as described above. Nevertheless, the results clearly suggest that the 5ЈEnd and 3ЈCSI PMO potently inhibit WN virus infection without apparent cytotoxicity at concentrations below 10 M.
A broad spectrum of antiviral activity of 3CSI PMO against mosquito-borne flaviviruses. Since the sequence targeted by the 3ЈCSI PMO is mostly conserved among mosquito-borne flaviviruses (17), we asked whether the 3ЈCSI PMO could inhibit mosquito-borne flaviviruses other than WN virus. Vero cells were infected with SLE, DEN-2, or YF virus (0.1 MOI), treated with 3ЈCSI PMO (7.5 M), and assayed for virus titers at 40 h posttreatment. As expected, virus titers derived from the 3ЈCSI PMO-treated infections were consistently lower than those derived from the untreated infections (Table 1) . The extent of reduction in virus titer correlated with the number of base pairs between the 3ЈCSI PMO and the targeted sequences of specific viruses. For example, targeted sequences from SLE and DEN-2 viruses have one and two mismatches with the 3ЈCSI PMO, and the corresponding suppression of virus titer was 500 and 640 fold upon 3ЈCSI PMO treatment, respectively. In contrast, the targeted sequence from YF virus and the 3ЈCSI PMO has eight mismatches (out of 22 nt), and the virus titer reduction was only 69 fold upon treatment. As controls, scramble PMO at the same concentration did not inhibit any tested viruses. The results showed that the 3ЈCSI PMO could broadly inhibit mosquito-borne flaviviruses. Experiments are ongoing to optimize the sequence of the CS1 PMO to improve its potency against various mosquito-borne flaviviruses.
To further analyze the antiviral specificity of PMOs, we examined the activities of 5ЈEnd, 3ЈCSI, and scramble PMOs against Western equine encephalitis (WEE) virus, an alphavirus from family Togaviridae. PMOs inhibit WN virus infection through specific suppression of viral translation or RNA replication. To study the mode of action of the two most potent 5ЈEnd and 3ЈCSI PMOs, we analyzed the inhibitors in a previously developed transient replicon system (25) . This replicon contains an Rluc gene fused in frame with the ORF in the position where the viral structural genes were deleted (RlucRep) (Fig. 6A) . We previously showed that transfection of BHK cells with RlucRep RNA yielded two distinctive Rluc peaks at 2 to 10 h and after 24 h p.t., respectively, representing viral translation and RNA replication of the transfected RlucRep (25) . This unique Rluc pattern could reliably be used to differentiate between RNA elements involved in viral translation and those involved in RNA replication (25, 52, 53) . To analyze the modes of action of the 5ЈEnd and 3ЈCSI PMOs, we incubated the RlucReptransfected BHK cells with PMOs immediately after electroporation. At 2 h (peak translation time of input RNA) and 72 h p.t. (RNA synthesis), cells were assayed for Rluc activities. The medium-active AUG-I and scramble PMOs were also included as controls. Compared with the mock-treated cells, 5ЈEnd PMO (at 7.5 M) suppressed Rluc activity by approximately 90% at 2 h p.t., leading to a background level of Rluc activity at 72 h p.t. As expected, AUG-I PMO (targeting the initiation codon of the ORF) inhibited Rluc activity by about 72% at 2 h p.t. Remarkably, 3ЈCSI did not substantially inhibit Rluc signal (96% of the mock treated) at 2 h p.t. but reduced Rluc activity to background level at 72 h p.t. As a control, the scramble PMO did not significantly affect Rluc signals at the 2-or 72-h time point. These results suggest that the 5ЈEnd and 3ЈCSI PMOs inhibit WN virus infection through two distinct mechanisms: inhibition of viral translation and RNA replication, respectively.
To further verify the specificity of the 5ЈEnd PMO-mediated inhibition on viral translation, we in vitro transcribed an RNA, designated 5Ј UTR-Rluc-3Ј UTR (Fig. 7A) , which contained a reporting Rluc (in-frame fused with the N-terminal 31 amino acids of the C protein) flanked by 5Ј and 3Ј UTRs. Compared with the replicon system shown in Fig. 6 , the 5Ј UTR-Rluc-3Ј UTR RNA allowed us to directly measure the effects of PMOs on translation. Transfection of BHK cells with such reporting RNA showed that Rluc signal peaked between 5 to 10 h p.t. (Fig. 7B) . Treatment of the 5Ј UTR-Rluc-3Ј UTR RNA-transfected cells with 5ЈEnd and AUG-I PMOs (at 7.5 M for 5 h) resulted in suppression of Rluc signals by approximately 82 and 52%, respectively (Fig. 7C) . In contrast, no significant suppression of Rluc activity was observed by treatment with the scramble PMO. These data agreed well with the replicon results (Fig.  6 ) and again demonstrated that the 5ЈEnd PMO exerts its antiviral activity through potent suppression of viral translation. c Virus titer reduction (fold) is the value of virus titer without PMO treatment divided by the value for virus titer with 3ЈCSI PMO treatment.
DISCUSSION
Prevention and treatment of infections by WN virus and other flaviviruses are public health priorities. A number of strategies can be used in the development of flavivirus therapies (44) . The goal of this study was to explore the feasibility of targeting RNA elements within the terminal regions of flavivirus genomes for antiviral drug discovery. Using WN virus as a model, we showed that antisense PMOs targeting various terminal regions of the WN virus genome had various antiviral activities. The two most potent PMOs were 5ЈEnd (targeting the 5Ј-terminal 20 nt) and 3ЈCSI (targeting a 3Ј element involved in genome cyclization). Treatment of WN virus-infected cells with 5ЈEnd or 3ЈCSI PMOs reduced virus titers by approximately 5 to 6 logs at a concentration of 5 M without apparent cytotoxicity. The 5ЈEnd and 3ЈCSI PMOs specifically inhibit viral translation and RNA synthesis, respectively.
Mechanisms of antisense PMOs. The efficacies of the antisense PMOs are dependent on many factors, such as (i) the efficiency of cellular delivery, (ii) the roles of the PMO-targeted sequences in the virus life cycle, and (iii) the accessibility of the targets for base pairing with the PMOs during viral infection. It is remarkable that the Arg-rich peptide P007 greatly facilitates the delivery of the PMOs into cultured cells (Fig. 1D) . The mechanism of the P007 peptide-mediated cellular uptake is currently unknown and merits further investigation. Other Arg-rich peptides were recently shown to enhance cellular delivery of PMOs (36) . For example, an NH 2 -(R) 9 (F) 2 -CONH 2 peptide was shown to enhance PMO delivery to inhibit mouse hepatitis virus (39) . However, the efficacy of the NH 2 -(R) 9 (F) 2 -CONH 2 -conjugated PMOs was reported to depend on the absence of serum in the culture medium. It was speculated that the highly charged peptide mediated attachment of PMOs to serum proteins, thus reducing the number of free PMO molecules competent for cell entry (39) . In contrast, the efficacy of the P007-conjugated PMOs designed for the present study did not show significant serum dependency, since all assays were performed in medium containing normal serum concentrations (from 2 to 10%). The improvement of this property in our study is likely due to the different composition of P007 peptide.
The PMOs evaluated in this study were designed to target specific terminal elements of the WN virus genome. Previous mutagenesis studies had shown that the targets for 5ЈEnd (19) , AUG-I and AUG-II (8), 5ЈCS (12, 20) , 3ЈCSI (3, 25, 56) , 3ЈLoop (52) , and 3ЈEnd (19, 53, 57) PMOs were essential for flavivirus replication. The biological relevance of the targets for Pskt (45) and 3ЈStem PMOs (2) has not been experimentally demonstrated. Screening of the PMOs in a replicon-reporting cell line (RlucNeoRep) (Fig. 2) showed that all molecules, except the 3ЈEnd PMO, have antiviral activities. These results indicate that regions involved in pseudoknot interaction (targeted by Pskt PMO) and EF1␣ binding interaction (targeted by 3ЈStem PMO) may be important for WN virus replication. However, it should be pointed out that, since the 20-to 23-nt PMOs interact with regions larger than the specific target site (i.e., the nucleotides involved in pseudoknot interaction and the major binding site for EF1␣), we cannot exclude the possibility that PMO base pairing with regions other than the targeted site is contributing to the antiviral activities.
The 5ЈEnd PMO exhibited the greatest antiviral activity through its suppression of viral translation ( Fig. 6 and 7) . Base-pairing interaction between the 5ЈEnd PMO and the 5Ј-terminal 20 nt of the genome may suppress the formation of the 43S preinitiation complex and ribosome scanning during viral translation (16) , leading to a suppression of initial viral translation. Interestingly, the translation suppression mediated by the 5ЈEnd PMO is greater than that mediated by the AUG-I PMO (decreases of 90 and 72%, respectively). The AUG-I and AUG-II PMOs were expected to block the interaction of the initiator AUG with the Met-tRNA i in the 43S preinitiation complex, thereby preventing the 60S ribosomal subunit from joining the preinitiation complex. However, a study using the Kunjin replicon showed that the conserved AG at the 5Ј terminus of the flavivirus genome is essential for RNA replication (most likely functioning at the step of plus-strand RNA synthesis) (19) . These results imply that, besides suppressing viral translation, the 5ЈEnd PMO also interferes with WN virus RNA synthesis. It is difficult to quantify the latter effect on viral inhibition, because the 5ЈEnd PMO-mediated reduction in translation could lead to suppression of RNA replication. The 3ЈCSI PMO exhibited a potent antiviral activity through its suppression of RNA replication, but not translation (Fig. 6 ). These data agree well with our previous results that mutations within the 3ЈCSI region (blocking the potential genome cyclization) do not significantly affect translation but completely abolish RNA replication (25) . Unexpectedly, the 5ЈCS PMO was less potent than the 3ЈCSI PMO (Fig. 2) . The 5ЈCS and 3ЈCSI PMOs are of similar length, G-C content, and design rationale to target either one of the two genome cyclization sequences. The lower efficacy of 5ЈCS PMO is likely due to its location at 32 nt downstream of the AUG initiation codon. A previous study has shown that PMOs targeting regions more than 20 nt downstream from the translation initiation site are much less effective in inhibiting viral translation. The processive translocation of the ribosome complex (which exhibits RNA helicase activity) could dislodge the bound PMOs from the target RNA (48) . In contrast, the binding site for the 3ЈCSI PMO is located 520 nt downstream of the stop codon of the ORF. Therefore, the 3ЈCSI PMO is less likely to be dislocated through ribosome collision.
It is puzzling that the 3ЈEnd PMO targeting the 3Ј-terminal 20 nt of the genome is not active against WN virus infection (Fig. 2) . Our previous results showed that the specific sequence and structure of the 3Ј-terminal 5-nt region of the genome are essential for WN virus replication (53) . We suspect that the 3Ј terminal nucleotides are constrained in a conformation that is not accessible for base pairing with the 3ЈEnd PMO. Antiviral assays. Development of reliable and authentic assays is essential for antiviral drug discovery. Besides the traditional virus titer reduction assay, we have employed three reporting antiviral assays in the present study. The type 1 assay uses a previously developed cell line containing a dualreporter replicon (RlucNeoRep) (Fig. 2A) . Incubation of the RlucNeoRep-reporting cells with a compound that blocks WN virus replication suppresses the Rluc expression level (26) . The utility of this reporting cell line as an antiviral assay was further confirmed in the present study, which screened the relative potencies of PMOs against WN virus replication ( Fig. 2B and  C) . The type 2 assay is based on a full-length reporting virus (RlucWN) (Fig. 3A) . We showed that, although the RlucWN vi-rus is not stable after multiple passages (Fig. 3B) , an early passage of this reporting virus can be used to screen for inhibitors of WN virus infection (Fig. 3C and 4A) . Compared with the traditional virus titer reduction assay (13, 18, 35) , both type 1 and type 2 assays are more sensitive and quantitative and can potentially be used for high-throughput screening of compound libraries.
When the two types of assays described above are compared, the RlucWN virus assay covers more steps of the virus life cycle (including virus entry and virion assembly) than does the RlucNeoRep cell line assay (which primarily involves viral translation and RNA replication). Therefore, the RlucWN virus assay can potentially be used to screen for inhibitors of viral entry and virion assembly. This extra feature of the RlucWN virus assay is particularly important, as recent studies suggest that besides viral replication, viral entry and particle assembly are also attractive targets for antiviral therapy (4, 21, 32, 33, 58, 59 ). For example, crystallographic studies showed that envelope proteins of DEN (32, 33) and TBE (4) viruses undergo a sequential structural change during the fusion-activating transition, a stage which could be targeted in the search for small-molecule inhibitors of flavivirus entry.
Efforts have been made to stabilize the RlucWN-reporting virus. One approach is to employ multiple rounds of plaque purification of replicating isolates that retain a high level of luciferase activity. The rationale of this approach is that viral evolution during multiple rounds of purification could confer adaptations that may accommodate the Rluc reporter, resulting in stable RlucWN isolates. We have performed such experiments by purifying Rluc-positive isolates (typically exhibiting smaller plaques than those derived from the wild-type virus). Disappointingly, after six rounds of plaque purification, the selected RlucWN isolates were still not stable (data not shown). An alternative approach is to insert the Rluc reporter within the ORF of the virus. One major advantage of this approach is the elimination of the IRES (required to drive the translation of the Rluc) that is present in our current construct, thus minimizing the potential packaging problem due to the oversized recombinant genome. The recent success of using transposons to select specific sites tolerable for insertion of a green fluorescent protein reporter in hepatitis C virus replicon (34) suggests that a similar approach could be useful for development of a stable reporting flavivirus.
The type 3 assay is based on a transient reporting replicon that can differentiate between viral translation and RNA replication (RlucRep) (Fig. 6A) (25) . Due to its transient nature, this assay is more sensitive to compound inhibition than the two assays described above. For example, the 5ЈCS, 3ЈCSI, and AUG-I PMOs completely knocked out the Rluc activity by 72 h p.t., indicating no replication of RlucRep (Fig. 6B) . In contrast, similar concentrations (5 to 10 M) of the same PMOs in the RlucNeoRep cell line (Fig. 2B and C) or RlucWN virus assay (Fig. 4A) did not suppress viral replication to background levels. Nevertheless, the results using the 5ЈCS, 3ЈCSI, AUG-I, and scramble PMOs clearly showed that the transient RlucRep system could be used to differentiate between the effects of PMOs on viral translation and RNA replication (Fig. 6B) .
In summary, a combination of the above three assays will greatly facilitate identification of potential inhibitors of any step of the viral life cycle and will be useful for determining the specific step at which an inhibitor functions. The potent anti-WN virus activities of the 5Ј End and 3ЈCSI PMOs clearly suggest for the first time that flavivirus infection could be inhibited by specific suppression of viral translation and RNA replication. Besides the PMO-mediated antiviral approach, other nucleic acid-based approaches have been previously reported against flaviviruses. Microinjection of modified phosphorothioate antisense agents into DEN-2 virus-infected cells reduced virus titers by 50 to 75% at 24 h postinfection (42) . Mosquitoes transduced with a recombinant Sindbis virus capable of expressing a 567-base antisense RNA to target DEN-2 virus genomic RNA were unable to support replication of DEN-2 virus in their salivary glands and therefore were not able to transmit the virus (40) . RNA silencing (small interfering RNA) was recently shown to suppress DEN-2 (1) and WN (30) viruses in tissue cultures. The potent inhibition of WN virus by the 5ЈEnd and 3ЈCSI PMOs described in this study has opened another avenue for antiviral therapy of flavivirus and potentially other RNA virus infections. Further development of these promising antiviral agents requires evaluation in animal models to examine in vivo potency, toxicity, metabolism, and pharmacokinetics. Finally, it is worth noting that, besides the antiviral utility, the PMOs can serve as a useful research tool to probe functions of viral RNA elements controlling translation and replication.
